Covagen Ag

Simon Brack

Dragan Grabulovski

Julian Bertschinger

Sarah Batey

Frédéric Mourlane

David Banner

Richard Woods

Isabella Attinger-Toller

Ulrike Von Der Bey

Michael Hennig

Michela Silacci Melkko

Ulrich Wüllner

Kristina Klupsch

Jörg Benz

Daniel Schlatter

Nadja Baenziger

Helen Hachemi

Babette Schade

Isabella Toller

Susann KÖNIG-Friedrich

Patricia Henne

The present invention relates to a binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells, wherein the binding molecule comprises: (a) a first binding (poly)peptide that specifically binds to a first epitope of said antigen expressed on tumor cells, wherein said first binding (poly)peptide is a Fyn SH3-derived polypeptide; and (b) a second binding (poly)peptide that specifically binds to a second epitope of said antigen expressed on tumor cells. The present invention further relates to a nucleic acid molecule encoding the binding molecule of the invention, a vector comprising said nucleic acid molecule as well as a host cell or a non-human host transformed with said vector. The invention further relates to a method of producing a binding molecule of the invention as well as to pharmaceutical and diagnostic composition. Moreover, the present invention also relates to the binding molecule, the nucleic acid molecule, the vector or the host cell of the invention for use in the treatment of tumors.

Binding molecules with antitumoral activity

The present invention relates to new IL-17 inhibiting polypeptides, corresponding fusion proteins, compositions and medical uses thereof.

IL-17 binding compounds and medical uses thereof

The present invention relates to a polypeptide binding to a chymase (EC 3.4.21.39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X)A(X)(X)(X)(X)(X)LSFHKGEKFQIL(X)(X)(X)(X) (X)(X)G(X)(X)WEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X) is R, N, Q, E, K, H, S, T, C, or D; (X) is E, T, D, Q, L, P, A, S, C, M, N, E, G, A, V or I; (X) is R, T, H, N, K, S, C, N or Q; (X) is S, W, T, C, N, Q, F or Y; (X) is T, H, L, F, C, S, M, N, Q, R, K, G, A, V, I, P, Y or W; (X) is D, Q, H, E, S, T, C, N, R or K; (X) is D, N, R, E, Q, S, T, C, K or D; (X) is M, W, G, F, A, T, C, S, N, Q, Y, V, L, I or P; (X) is T, H, S, D, C, N, Q, R, K, E or absent; (X) is V, T, Q, G, A, L, I, P, S, C, M, N or absent; (X) is P, A, D, G, K, V, L, I, E, R, M, H or absent; (X) is N, V, P, I, E, T, S, A, G, L, C, M, Q or D; (X) is D, E, T, P, G, A, V, L, I, S, C, M, N or Q, and (X) is W, Y, L, G, A, V, I, P, M, or F; (b) an amino acid sequence which is at least 85% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X) to (X).

Chymase binding compounds and medical uses thereof

Growing community of inventors

Winterthur, Switzerland

Simon Brack